Cosmas Rinaldi Adithya Lesmana

Dr. Cosmas Rinaldi Adithya Lesmana


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2021 in Livers
Verified
Journal Article
Open access
PDF file
SNSaut Horas H Nababan
Saut Horas H Nababan
KKKemal Fariz Kalista
Kemal Fariz Kalista
CJChyntia Olivia Maurine Jasirwan
Chyntia Olivia Maurine Jasirwan
JKJuferdy Kurniawan
Juferdy Kurniawan
CLCosmas Rinaldi Adithya Lesmana
Cosmas Rinaldi Adithya Lesmana
RGRino A. Gani
Rino A. Gani
Background: Esophageal varices occur at middle to advanced stages of cirrhosis and are associated with increased mortality due to their potential for rupture and bleeding. The aim of this study is to examine the accuracy of a surrogate marker, Mac-2 binding protein glycosylation isomer (M2BPGi), for screening high-risk esophageal varices in cirrhotic patients. Methods: Ninety-four cirrhotic patients who underwent endoscopy screening at Cipto Mangunkusumo Hospital, Jakarta, Indonesia were included. Patients with a history of ligation, portal vein thrombosis, or hepatocellular carcinoma were excluded. All enrolled patients underwent ultrasonography, transient elastography, and laboratory tests. The HISCL-5000 Sysmex analyzer was used to measure M2BPGi levels. Results: Of these 94 patients, 27 had high-risk esophageal varices and 67 had non-high-risk esophageal varices. M2BPGi levels were higher in patients with high-risk esophageal varices compared with those with non-high-risk esophageal varices (cutoff index (COI) of 11.4 vs. 3.7, p < 0.001). The sensitivity, specificity, positive predictive value, and negative predictive value of M2BPGi with a cutoff value of 5 COI was 92.6%, 70.1%, 55.6%, and 95.9%, respectively. Conclusions: M2BPGi could be used as a non-invasive surrogate marker for ruling out high-risk esophageal varices in cirrhotic patients. This method is cheap and non-invasive and could be used as a screening tool in resource-limited settings.

7 March 2026 in JGH Open
Verified
Journal Article
Open access
PDF file
SSStephen Dario Syofyan
Stephen Dario Syofyan
KKKenoah Kovara
Kenoah Kovara
NLNicholas Putra Lesmana
Nicholas Putra Lesmana
JWJosia Nathanael Wiradikarta
Josia Nathanael Wiradikarta
JSJoshua Francisco Syofyan
Joshua Francisco Syofyan
CLCosmas Rinaldi Adithya Lesmana
Cosmas Rinaldi Adithya Lesmana
Hepatocellular carcinoma remains a major problem in Asia as well as globally. Most patients present at the late stage of the disease. Currently, several types of immunotherapy (IT) have been studied for its efficacy in treating hepatocellular carcinoma, such as atezolizumab and bevacizumab, which work as inhibitors in checkpoints and inhibitors in VEGF, respectively. In recent studies, this specific combination of therapy has shown a better progression free survival (PFS) rate and overall survival (OS) compared to the current therapy sorafenib. However, this treatment modality carries several potential adverse effects, such as gastrointestinal bleeding and bleeding esophageal varices (BOV). We present a series of seven HCC patients, where six patients had esophageal varices and one patient had large gastroesophageal varices who underwent endoscopy evaluation and therapeutic endoscopy including endoscopic ultrasound guided before IT. All patients underwent IT after therapeutic endoscopy within less than a week. No bleeding was observed during and after IT. These cases demonstrate the endoscopic ultrasound method in HCC patients.